Standout Papers
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study (2018)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
Immediate Impact
46 by Nobel laureates 8 from Science/Nature 169 standout
Citing Papers
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Lung cancer
2021 Standout
Works of John D. Powderly being referenced
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
2018 Standout
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| John D. Powderly | 6339 | 3476 | 2126 | 150 | 7.7k | |
| Evan J. Lipson | 5692 | 2178 | 1543 | 123 | 7.4k | |
| Sumit K. Subudhi | 3887 | 3532 | 1701 | 105 | 7.0k | |
| Marc R. Theoret | 4347 | 2733 | 1098 | 135 | 6.5k | |
| Yosuke Togashi | 4091 | 1892 | 2276 | 152 | 6.2k | |
| Junzo Hamanishi | 4334 | 3500 | 937 | 137 | 7.1k | |
| Luciana Molinero | 6401 | 3345 | 2140 | 101 | 8.9k | |
| Hossein Borghaei | 6996 | 1833 | 4499 | 255 | 8.8k | |
| Michael A. Curran | 3866 | 3553 | 942 | 124 | 6.7k | |
| Raanan Berger | 4115 | 1612 | 1893 | 158 | 7.1k | |
| Joseph I. Clark | 3742 | 2350 | 3056 | 120 | 7.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...